INFLA HARMONY™: Chronic Pain Support

No. France’s food safety agency, ANSES, states this as a definition, not a note of caution: “A food supplement is not a medicine, and can therefore not, by definition, claim any therapeutic effect.”

Assurance Maladie, France’s national health insurance body, explicitly places these products in the category of self-medication: “Spontaneous consumption of food supplements, or their use as an alternative therapeutic approach, can amount to self-medication. Indeed, these products are generally sold with claims that often point towards improved health and well-being. Yet they can interact with one or more medicines.”

It also describes, regarding self-medication continued beyond the recommended duration, the exact mechanism we refuse to encourage: “this behaviour can lead to delaying a consultation during which the doctor could detect a more serious problem.”

Pain that persists should be assessed and treated through a consultation. A food supplement replaces neither a diagnosis, nor a treatment, nor the advice of a doctor, pharmacist or physiotherapist. If this is your situation, start by making an appointment.

Sources (French agencies, quotes translated from French): ANSES, “Food supplements: the need for informed consumption,” published 21 March 2025, anses.fr/fr/content/les-complements-alimentaires-necessite-dune-consommation-eclairee; Assurance Maladie, “Self-treating with self-medication,” 11 September 2025, ameli.fr/assure/sante/medicaments/utiliser-recycler-medicaments/automedication. Accessed 22 August 2026.

France’s National Authority for Health (HAS) uses the definition of the International Association for the Study of Pain: chronic pain is “pain that persists or recurs for more than 3 months.” It adds a sentence that entirely reframes the subject: “The aim of managing it is rarely to resolve the pain, but above all to reduce the resulting disability and improve the patient’s quality of life.”

Inserm, the French national medical research institute, says the same thing differently: “If acute pain persists beyond three months, it becomes chronic pain. This sensation then loses its meaning as a warning signal: pain is no longer a symptom but becomes an illness in itself.”

This is why you will read no sentence on this page linking this product to pain. What these two institutions are describing is not a passing discomfort, and it is not treated with a foodstuff.

Sources (French institutions, quotes translated from French): HAS, “Care pathway for a person with chronic pain,” guide of January 2023, has-sante.fr/jcms/p_3218057; Inserm, “Pain” topic page, inserm.fr/dossier/douleur. Accessed 22 August 2026.

Your GP, first. France’s National Authority for Health describes a pathway organised into three levels, and is explicit about the entry point: “Except in exceptional cases, a first assessment of chronic or worsening pain must be carried out by the GP.”

The first level is community care, and it is not a mere filter: “Level 1, community care, must be able to manage most chronic pain patients and/or most of their care pathway.” The team involved “mainly comprises the GP, the nurse, the physiotherapist, the pharmacist and the psychologist.”

Levels 2 and 3 are chronic pain centres, called on by the doctor “in cases of stubborn chronic pain, that is, pain resistant to well-conducted level 1 treatments.”

Source (French institution, quotes translated from French): HAS, “Care pathway for a person with chronic pain,” factsheet validated by the Board on 12 December 2024 and guide of January 2023, has-sante.fr/jcms/p_3218057. Accessed 22 August 2026.

Many, and that is precisely why the subject deserves better than a sales pitch. The December 2024 factsheet from France’s National Authority for Health aims to address “the needs of nearly 20 million people, adults and children, suffering from chronic pain in France.” Its guide, drawing on the STOPNEP study, gives a prevalence of “19.9%, or around 12 million people in France” for moderate to severe pain alone in adults.

Inserm gives a similar figure with a social nuance: “chronic pain affects around 30% of adults,” based on a study of 30,155 people representative of the general population; “in two-thirds of cases, the pain is of moderate to severe intensity,” and “it affects women and less advantaged socio-professional groups more.”

HAS adds that “pain is the leading reason for consultations in general practice and in emergency departments.”

Sources (French institutions, quotes translated from French): HAS, “Care pathway for a person with chronic pain” factsheet, December 2024, and guide of January 2023, has-sante.fr/jcms/p_3218057; Inserm, “Pain” topic page, inserm.fr/dossier/douleur. Accessed 22 August 2026.

Because pain that persists almost never has a single cause. France’s National Authority for Health uses the biopsychosocial model: “the development, persistence and worsening of chronic pain are linked to numerous interlinked factors,” which it classifies as biological, psychological and social.

It draws a practical conclusion from this: “The management of chronic pain is necessarily patient-centred. It is developed and carried out with the patient’s agreement and participation.” This care is “sometimes curative, most often rehabilitative, multimodal and long-term. It combines drug and non-drug treatments, and possibly interventional techniques.”

HAS adds a safeguard that we are glad to repeat: this care must “be based on a validated scientific approach” and “guard against any drift towards so-called unconventional interventions.”

Source (French institution, quotes translated from French): HAS, guide of January 2023 and factsheet of December 2024, “Care pathway for a person with chronic pain,” has-sante.fr/jcms/p_3218057. Accessed 22 August 2026.

These are the chronic pain assessment and treatment consultations and centres, abbreviated SDC by France’s National Authority for Health. You cannot refer yourself: it is the primary care doctor who refers, “using the request form for an opinion or a consultation in a chronic pain centre for a person with chronic pain.”

HAS distinguishes two levels. Level 2 handles “stubborn, chronic or worsening pain that does not respond to well-conducted standard treatments.” Level 3 “is called on by level 2 for difficult situations beyond its capacity for assessment or treatment.”

One point is worth remembering: whatever level is reached, “follow-up of the patient by the GP and the primary care team (ESP) at level 1 continues.”

Source (French institution, quotes translated from French): HAS, factsheet of December 2024 and guide of January 2023, “Care pathway for a person with chronic pain,” has-sante.fr/jcms/p_3218057. Accessed 22 August 2026.

No, and this is probably the most useful answer on this page. France’s National Authority for Health observes that “care is provided too late by international standards,” both in the community and in hospitals, and that people affected “access chronic pain centres after several years (5 years on average),” “which makes care more complex, longer, and the scope for improvement more limited.” Once referred, they “face waiting times of 8 months or more for a first consultation.”

The Authority sets this as a goal: “Identifying pain, screening for factors that lead to it becoming chronic, and managing pain within timeframes consistent with international recommendations should, over time, reduce the incidence and prevalence of chronic pain in the population and its impact on those affected.”

In other words, the delay that matters happens before the waiting list. It starts on the day you make an appointment.

Source (French institution, quotes translated from French): HAS, guide of January 2023 and factsheet of December 2024, “Care pathway for a person with chronic pain,” has-sante.fr/jcms/p_3218057. Accessed 22 August 2026.

No, and this is what ANSES, France’s food safety agency, states in an opinion devoted to food supplements containing anti-inflammatory plants: “Inflammation is a natural defence process and does not need to be fought when it is not excessive.”

The same opinion sets out a limit that we repeat as it stands: “Given the available data, it cannot be excluded that consuming plants with anti-inflammatory or immunomodulatory properties may hinder the body’s natural defences.” The Agency recommends that consumers “refer to their doctor if plants covered by this opinion are identified in the composition of a supplement they take, particularly if they are being treated for a chronic inflammatory condition.”

Turmeric and boswellia are among the plants covered by this opinion. Two of the five actives in this formula are therefore directly concerned. We would rather write this for you than let you discover it.

Source (French agency, quotes translated from French): ANSES, opinion on referral No. 2020-SA-0045, 10 April 2020, anses.fr/system/files/NUT2020SA0045.pdf. Accessed 22 August 2026.

It is markedly less enthusiastic than the market. The best-documented example is vitamin D, despite being heavily studied on this topic. A Cochrane review updated in May 2015 pooled ten double-blind randomised trials and 811 participants. Its conclusion: “Based on this evidence, a large beneficial effect of vitamin D across different chronic painful conditions is unlikely.” The authors note that “overall, there was no consistent pattern that vitamin D treatment was associated with greater efficacy than placebo in any chronic painful condition (low quality evidence).”

This says nothing about our formula, good or bad: we found no Cochrane review covering this combination of actives. It simply shows that solid evidence is scarce in this area, and that a brand claiming otherwise is going beyond what the literature supports.

Source: Straube S, Derry S, Straube C, Moore RA, “Vitamin D for the treatment of chronic painful conditions in adults,” Cochrane Database of Systematic Reviews 2015, Issue 5, Art. No. CD007771, published 6 May 2015, cochrane.org/evidence/CD007771. Accessed 22 August 2026.

This is the only area where Cochrane has produced an overall synthesis for chronic pain, and the result deserves to be read as it stands. The overview published in 2017 pooled 21 Cochrane reviews, 381 studies and 37,143 participants. The authors’ conclusion: “The quality of the evidence examining physical activity and exercise for chronic pain is low. This is largely due to small sample sizes and potentially underpowered studies.” They add: “The available evidence suggests physical activity and exercise is an intervention with few adverse events that may improve pain severity and physical function, and consequent quality of life.”

Weak evidence is not evidence to the contrary: it means research has not yet reached the sample size needed to settle the question. What is right for your situation is for your doctor to decide, not a product page.

Source: Geneen LJ, Moore RA, Clarke C, Martin D, Colvin LA, Smith BH, “Physical activity and exercise for chronic pain in adults: an overview of Cochrane Reviews,” Cochrane Database of Systematic Reviews 2017, Issue 4, Art. No. CD011279, published 24 April 2017, cochrane.org/evidence/CD011279. Accessed 22 August 2026.

Because that is its nature. ANSES, France’s food safety agency, describes it as follows, through the voice of the coordinator of its expert assessment: “Curcumin has very low bioavailability, meaning it passes into the bloodstream with difficulty and is eliminated very quickly by the body. Manufacturers have developed various formulations to improve this bioavailability and so increase the effects of curcumin.”

The Agency classifies these formulations into two families. The classic forms: “turmeric rhizome powder,” “turmeric extracts, whether or not enriched in curcumin.” The new forms that increase bioavailability: “combinations of curcumin with piperine or turmeric essential oil,” then “more elaborate forms: phytosomal complex, micelle, colloidal nanoparticles, cyclodextrin encapsulation…”

The curcumin used here, Longvida®, is encapsulated in a complex of phospholipids and fatty acids. It therefore belongs to the second family. This has practical consequences, detailed in the next question.

Source (French agency, quotes translated from French): ANSES, “Adverse effects linked to the consumption of food supplements containing turmeric,” 27 June 2022, anses.fr/fr/content/des-effets-indesirables-lies-la-consommation-de-complements-alimentaires-contenant-du. Accessed 22 August 2026.

This is the question we wish we had seen asked elsewhere. ANSES notes that “EFSA has set the acceptable daily intake (ADI) at 180 mg of curcumin per day for a 60 kg adult” and that it has itself “determined that the amount provided by food supplements should remain below 153 mg per day for a 60 kg adult.”

Then comes the caveat: “the Agency stresses that this figure is valid only for food supplement formulations containing curcumin in classic form.” And the warning: “Even where they do not appear to exceed the ADI, these new formulations may carry a risk of adverse health effects by increasing the bioavailability of curcumin in the body. To date, the food supplement label rarely states whether the formulation is classic or new.”

Our label states it, and so does this page: the formula provides 92 mg of curcuminoids per daily dose of four capsules, in encapsulated form. The 153 mg benchmark therefore does not apply to it as it stands. Do not exceed the stated dose, and seek medical advice if you are on ongoing treatment.

Source (French agency, quotes translated from French, figures originally set by EFSA): ANSES, “Adverse effects linked to the consumption of food supplements containing turmeric,” 27 June 2022, anses.fr/fr/content/des-effets-indesirables-lies-la-consommation-de-complements-alimentaires-contenant-du. Accessed 22 August 2026.

This question is not settled on a product page. It is settled with your doctor or pharmacist, with the composition in front of them.

What we can do is give you the elements. ANSES, France’s food safety agency, “advises against the consumption of turmeric-based food supplements by people suffering from disorders of the biliary tract.” It adds: “there is a risk linked to interactions between curcumin and certain medicines such as anticoagulants, anticancer medicines and immunosuppressants. Their efficacy or safety could be affected. The Agency therefore advises against the consumption of food supplements containing turmeric by people treated with these medicines without medical advice.”

In its 2020 opinion, the Agency also recommends “avoiding multiple sources of exposure to these plants, owing to the risk of cumulative intake and additive effects that could lead to adverse effects.”

The full composition, active by active, with amounts and standardisation, is set out in the Ingredients tab on this page. Show it to them.

Sources (French agency, quotes translated from French): ANSES, article of 27 June 2022, anses.fr/fr/content/des-effets-indesirables-lies-la-consommation-de-complements-alimentaires-contenant-du; ANSES, opinion on referral No. 2020-SA-0045, 10 April 2020, anses.fr/system/files/NUT2020SA0045.pdf. Accessed 22 August 2026.

Yes, and it would be dishonest not to state this on the page of a product that contains it. ANSES, France’s food safety agency, reports that “Italy has recorded around twenty cases of hepatitis involving food supplements containing turmeric” and that “in France, ANSES’s nutrivigilance scheme has recorded more than 100 reports of adverse effects potentially linked to the consumption of food supplements containing turmeric or curcumin, including 15 cases of hepatitis.”

This nutrivigilance scheme has existed since 2009 and works in both directions: it “makes it possible to collect and identify adverse effects reported by health professionals, in particular doctors and pharmacists, manufacturers or distributors, as well as any member of the public.” If you notice an adverse effect, report it.

Sources (French agency, quotes translated from French): ANSES, article of 27 June 2022, anses.fr/fr/content/des-effets-indesirables-lies-la-consommation-de-complements-alimentaires-contenant-du; ANSES, “Food supplements: the need for informed consumption,” 21 March 2025, anses.fr/fr/content/les-complements-alimentaires-necessite-dune-consommation-eclairee. Accessed 22 August 2026.

ANSES, France’s food safety agency, publishes five pieces of advice, which we reproduce without editing: “Seek advice from a health professional,” “Avoid prolonged, repeated or multiple use,” “Follow the conditions of use,” “Be wary of products presented as miracle cures,” “Favour products sold through the best-controlled channels.”

It also recommends starting with a question: “Before consuming a food supplement, the first question to ask is: do I really need it?”

On the label itself, three figures are worth looking for on each plant: the amount of extract per daily dose, the standardisation of that extract, and the nature of the extraction process. All three appear on this page. Their absence elsewhere is information in itself.

Source (French agency, quote translated from French): ANSES, “Food supplements: the need for informed consumption,” published 21 March 2025, anses.fr/fr/content/les-complements-alimentaires-necessite-dune-consommation-eclairee. Accessed 22 August 2026.

Because European law strictly governs what a food is entitled to claim. EFSA states the objective of Regulation 1924/2006: “One of the key objectives of this Regulation is to ensure that any claim made on a food label in the EU is clear and substantiated by scientific evidence.” And it is the Authority that carries out this verification: “EFSA is responsible for verifying the scientific substantiation of the submitted claims.”

On the French side, ANSES, France’s food safety agency, summarises the situation: claims “are strictly governed by European regulation,” and “to date, a limited number of health claims are authorised.” None of them covers the plants in this formula.

When a page nonetheless promises you a result, it does not have access to some science that others lack. It has simply chosen not to stay within the framework.

Sources: EFSA, “Health claims” topic page, efsa.europa.eu/en/topics/topic/health-claims; ANSES (French agency, quote translated from French), “Food supplements: the need for informed consumption,” 21 March 2025, anses.fr/fr/content/les-complements-alimentaires-necessite-dune-consommation-eclairee. Accessed 22 August 2026.

One nuance exists, however, and we apply it. Among the claims still pending are statements relating to joint health, usable under the transitional regime provided for in Article 28 of the Regulation. On this basis, and this basis only, this page states that turmeric and boswellia contribute to joint health. No statement referring to a disease is possible, and you will find none here.

It is not recommended in cases of biliary obstruction or biliary function disorders, for pregnant or breastfeeding women, for people with diabetes, or when taking anticoagulants, anticancer medicines or immunosuppressants.

Do not exceed the recommended daily dose. This product is not a substitute for a varied, balanced diet or a healthy lifestyle. Keep out of reach of young children.

If you are on any ongoing treatment, seek the advice of a doctor or pharmacist before the first dose.

Every page in this range describes one and the same product: the same actives, the same amounts, the same 120-capsule bottle, the same dose of four capsules a day. Nothing changes in the jar. What changes is the angle from which we explain the composition, and the path by which you arrived here.

This page is written for readers who want to understand a formula before choosing one: extraction forms, standardisation, regulatory limits, precautions. Other pages cover the same composition from a different angle, drawing on the same public sources: the page written for readers over 50, the tendinitis supplement page, the page that details the comparison criteria, the page devoted to days spent sitting, the page focused on the lower back.

Whichever you choose, the full composition appears in the Ingredients tab on this page. Four options: single purchase, a pack of 2, a pack of 3, or a monthly subscription at €29.90 instead of €39.90, cancellable at any time.

On the topic of joints, European regulation authorises one statement under the pending claims: boswellia contributes to the health of joints and bones. This formula provides 307 mg per daily dose, as a concentrated extract standardised to 65% boswellic acids, providing 200 mg of boswellic acids.

Beyond this sentence, nothing more can be stated, by us or by anyone else.

The same framework applies: turmeric contributes to joint health. This formula provides 400 mg of Longvida® curcumin, including 92 mg of curcuminoids, extracted using the patented “Solid Lipid Curcumin Particle” technology.

As ordinary curcumin is very poorly absorbed, it was the form that guided this choice, not the raw quantity. Here again, nothing else can be stated.